EnerVenue | $300,000,000 | (Apr 3, 2026)
Acurion, Inc. | $4,300,000 | (Apr 3, 2026)
Gander Robotics | $1,100,000 | (Apr 3, 2026)
Certified by Founder
Lodge
Vima Therapeutics
start up
United States
- Cambridge, Massachusetts
- 30/05/2025
- Series A
- $60,000,000
Vima Therapeutics is a clinical-stage biotechnology company pioneering a new era in the treatment of dystonia and related movement disorders.
We are advancing VIM0423, a potential first-in-class oral therapy for dystonia, with the goal of helping individuals regain control of their movements by targeting the underlying cause of the disease.
Vima brings together a team of physicians, scientists, and drug developers with deep expertise in movement disorders and a shared commitment to deliver a meaningful oral therapy for patients.
- Industry Biotechnology Research
- Website https://vimatx.com/
- LinkedIn https://www.linkedin.com/company/vima-therapeutics/
daydream | $15,000,000 | (Apr 3, 2026)
Numos | $4,250,000 | (Apr 3, 2026)
Alien | $7,100,000 | (Apr 3, 2026)
Monarch Quantum | $55,000,000 | (Apr 3, 2026)
Sona(UK) | $45,000,000 | (Apr 2, 2026)
Linx Security | $50,000,000 | (Apr 2, 2026)
Earlyasset | $2,000,000 | (Apr 2, 2026)
Rowan(US) | $3,300,000 | (Apr 2, 2026)
Whirl AI | $8,900,000 | (Apr 2, 2026)